title: Correlation of 18-F-fluorodeoxyglucose (FDG) accumulation with glucose transporter (Glut-1) expression in esophageal squamous cell carcinoma.
abstract: BACKGROUND
  We previously reported that positron emission tomography (PET) with 18-F-fluorodeoxyglucose (FDG) might be a useful tool for evaluating the stage of esophageal squamous cell carcinoma (SCC), and that FDG-PET shows greater accuracy in the diagnosis of lymph node metastasis than computed tomography. Further, we elucidated the relationships among FDG-PET performance, glucose transporter (Glut)-1 expression and serum levels of the tumor markers carcinoembryonic antigen (CEA), cytokeratin 19 fragment (CYFRA) and squamous cell carcinoma antigen (SCC-Ag) in esophageal SCC.
  
  
  METHODS
  We studied 44 patients with thoracic esophageal SCC who had undergone radical esophagectomy. Immunohistochemical analysis was used to detect the expression of Glut-1 in resected specimens and FDG accumulation was assessed by FDG-PET scan.
  
  
  RESULTS
  FDG uptake in the primary tumor was found in 34 out of 44 (77.3%) patients. No significant correlation was observed between SUVs and the tumor markers CEA, CYFRA and SCC-Ag. The survival rate in patients with high FDG uptake (SUV > 3) was significantly lower than in cases with low FDG uptake (SUV < 3) (p < 0.01). A significant correlation was observed between SUV and Glut-1 expression (p < 0.05). The prognosis in patients with both low Glut-1 expression and low FDG uptake tended to be more favorable than in patients with high Glut-1 expression and/or high FDG uptake.
  
  
  CONCLUSIONS
  Glut-1 expression was related to FDG uptake, and assessment of both FDG uptake and Glut-1 expression might be useful for providing prognostic information in patients with esophageal SCC.
authors.affiliation: Department of Surgery I, Gunma University Faculty of Medicine, 3-39-22, Showamachi, Maebashi, Gunma, 371-8511, Japan. hiroyuki@po.wind.ne.jp
authors.forename: Hiroyuki
authors.initials: H
authors.lastname: Kato
authors.forename: Junko
authors.initials: J
authors.lastname: Takita
authors.forename: Tatsuya
authors.initials: T
authors.lastname: Miyazaki
authors.forename: Masanobu
authors.initials: M
authors.lastname: Nakajima
authors.forename: Yasuyuki
authors.initials: Y
authors.lastname: Fukai
authors.forename: Norihiro
authors.initials: N
authors.lastname: Masuda
authors.forename: Minoru
authors.initials: M
authors.lastname: Fukuchi
authors.forename: Ryokuhei
authors.initials: R
authors.lastname: Manda
authors.forename: Hitoshi
authors.initials: H
authors.lastname: Ojima
authors.forename: Katsuhiko
authors.initials: K
authors.lastname: Tsukada
authors.forename: Hiroyuki
authors.initials: H
authors.lastname: Kuwano
authors.forename: Noboru
authors.initials: N
authors.lastname: Oriuchi
authors.forename: Keigo
authors.initials: K
authors.lastname: Endo
mesh_terms: D000328:Adult; D000368:Aged; D000951:Antigens, Neoplasm / Q000097:blood; D014408:Biomarkers, Tumor / Q000097:blood; D002272:Carcinoembryonic Antigen / Q000097:blood; D002294:Carcinoma, Squamous Cell / Q000097:blood / Q000000981:diagnostic imaging / Q000378:metabolism*; D004938:Esophageal Neoplasms / Q000097:blood / Q000000981:diagnostic imaging / Q000378:metabolism*; D019788:Fluorodeoxyglucose F18 / Q000493:pharmacokinetics*; D051272:Glucose Transporter Type 1; D006801:Humans; D053539:Keratin-19; D007633:Keratins; D008875:Middle Aged; D009004:Monosaccharide Transport Proteins / Q000096:biosynthesis*; D011379:Prognosis; D019275:Radiopharmaceuticals / Q000493:pharmacokinetics*; D015843:Serpins; D014055:Tomography, Emission-Computed
chemical_list: D000951:Antigens, Neoplasm; D014408:Biomarkers, Tumor; D002272:Carcinoembryonic Antigen; D051272:Glucose Transporter Type 1; D053539:Keratin-19; D009004:Monosaccharide Transport Proteins; D019275:Radiopharmaceuticals; C495677:SLC2A1 protein, human; D015843:Serpins; C102012:antigen CYFRA21.1; C051072:squamous cell carcinoma-related antigen; D019788:Fluorodeoxyglucose F18; D007633:Keratins